Label: GLYCOPYRROLATE- glycopyrrolate tablet 

  • Label RSS
  • NDC Code(s): 63304-210-01, 63304-210-10, 63304-210-11, 63304-210-30, view more
    63304-210-69, 63304-211-01, 63304-211-10, 63304-211-11, 63304-211-30, 63304-211-69
  • Packager: Ranbaxy Pharmaceuticals Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 01/13

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Glycopyrrolate tablets, USP contain the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide. The molecular formula is C19H28BrNO3 and the molecular weight is 398.33.

    Its molecular structure is as follows:This is the molecular structure

    Each tablet for oral administration contains 1 mg or 2 mg glycopyrrolate, USP. Inactive Ingredients: Dibasic calcium phosphate anhydrous, lactose monohydrate, magnesium stearate, povidone, sodium starch glycolate.

    Close
  • CLINICAL PHARMACOLOGY

    Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

    Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.

    The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

    Close
  • INDICATIONS AND USAGE

    For use as adjunctive therapy in the treatment of peptic ulcer.

    Close
  • CONTRAINDICATIONS

    Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Glycopyrrolate tablets, USP are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

    Close
  • WARNINGS

    In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with use of glycopyrrolate.

    Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

    Glycopyrrolate may produce drowsiness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug.

    Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.

    Pregnancy

    The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

    Pediatric Use

    Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

    Close
  • PRECAUTIONS

    Use glycopyrrolate with caution in the elderly and in all patients with:

    • Autonomic neuropathy.
    • Hepatic or renal disease.
    • Ulcerative colitis–large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate “toxic megacolon,” a serious complication of the disease.
    • Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.
    • Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition.

    Drug Interactions

    There are no known drug interactions.

    Close
  • ADVERSE REACTIONS

    Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilatation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

    Glycopyrrolate is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.

    Close
  • OVERDOSAGE

    The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.

    1. To guard against further absorption of the drug–use gastric lavage, cathartics and/or enemas.
    2. To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.)–utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.
    3. To combat hypotension–use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.
    4. To combat respiratory depression–administer oxygen; utilize a respiratory stimulant such as Dopram® i.v.; artificial respiration.
    Close
  • DOSAGE AND ADMINISTRATION

    The dosage of glycopyrrolate tablets, USP should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.

    Glycopyrrolate 1 mg tablets. The recommended initial dosage of glycopyrrolate tablets, USP for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may require two tablets at bedtime to assure overnight control of symptoms. For maintenance, a dosage of one tablet twice a day is frequently adequate.

    Glycopyrrolate 2 mg tablets. The recommended dosage of glycopyrrolate tablets, USP for adults is one tablet two or three times daily at equally spaced intervals.

    Glycopyrrolate tablets, USP are not recommended for use in pediatric patients under the age of 12 years.

    Close
  • HOW SUPPLIED

    Glycopyrrolate tablets, USP 1 mg are white to off-white, round, flat faced, beveled edge, uncoated tablets debossed with ‘RE’ and ‘28’on one side and bisect on the other side. Glycopyrrolate tablets, USP 1 mg are available as

    NDC 63304-210-30 Bottles of 30

    NDC 63304-210-01 Bottles of 100

    NDC 63304-210-10 Bottles of 1000

    NDC 63304-210-69 Box of 10 Unit-dose

    Glycopyrrolate tablets, USP 2 mg are white to off-white, round, flat faced, beveled edge, uncoated tablets debossed with ‘RE’ and ‘29’on one side and bisect on the other side. Glycopyrrolate tablets, USP 2 mg are available as

    NDC 63304-211-30 Bottles of 30

    NDC 63304-211-01 Bottles of 100

    NDC 63304-211-10 Bottles of 1000

    NDC 63304-211-69 Box of 10 Unit-dose

    Store at 20° - 25° C (68° - 77° F) [See USP Controlled Room Temperature].

    Dispense in tight container.

    To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    * Dopram® is a registered trademark of Baxter Healthcare Corporation.

    Manufactured for:

    Ranbaxy Pharmaceuticals Inc.

    Jacksonville, FL 32257 USA

    January 2013 FDA-03

    Close
  • PATIENT PACKAGE PRINCIPAL DISPLAY PANEL

    This is the 1mg-100s label

    1 mg 100’s bottle label

    This is the 2 mg-100s label

    2 mg 100’s bottle label

    Close
  • INGREDIENTS AND APPEARANCE
    GLYCOPYRROLATE 
    glycopyrrolate tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:63304-210
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    GLYCOPYRROLATE (GLYCOPYRRONIUM) GLYCOPYRROLATE 1 mg
    Inactive Ingredients
    Ingredient Name Strength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE  
    LACTOSE MONOHYDRATE  
    MAGNESIUM STEARATE  
    POVIDONE  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    Product Characteristics
    Color white (white to off-white) Score 2 pieces
    Shape ROUND (flat faced, beveled edge) Size 8mm
    Flavor Imprint Code RE28
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:63304-210-30 30 in 1 BOTTLE
    2 NDC:63304-210-01 100 in 1 BOTTLE
    3 NDC:63304-210-10 1000 in 1 BOTTLE
    4 NDC:63304-210-69 1 in 1 BOX
    4 NDC:63304-210-11 10 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040844 08/18/2009
    GLYCOPYRROLATE 
    glycopyrrolate tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:63304-211
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    GLYCOPYRROLATE (GLYCOPYRRONIUM) GLYCOPYRROLATE 2 mg
    Inactive Ingredients
    Ingredient Name Strength
    ANHYDROUS DIBASIC CALCIUM PHOSPHATE  
    LACTOSE MONOHYDRATE  
    MAGNESIUM STEARATE  
    POVIDONE  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    Product Characteristics
    Color white (white to off-white) Score 2 pieces
    Shape ROUND (flat faced, beveled edge) Size 10mm
    Flavor Imprint Code RE29
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:63304-211-30 30 in 1 BOTTLE
    2 NDC:63304-211-01 100 in 1 BOTTLE
    3 NDC:63304-211-10 1000 in 1 BOTTLE
    4 NDC:63304-211-69 1 in 1 BOX
    4 NDC:63304-211-11 10 in 1 BLISTER PACK
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040844 08/18/2009
    Labeler - Ranbaxy Pharmaceuticals Inc. (937890044)
    Registrant - Ranbaxy Pharmaceuticals Inc. (937890044)
    Establishment
    Name Address ID/FEI Business Operations
    Ohm Laboratories Inc. 184769029 manufacture(63304-210, 63304-211)
    Close